irdabisant
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT01903824)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Histamine H3 receptorANTAGONIST
HRH3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)[nH]n2)cc1- Mol. weight
- 313.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1829335 ↗
Also known as
- 6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-2h-pyridazin-3-one
- cep26401
- cep 26401
- cep-26401
- cep-26401
- cep-26401
- cep-26401
- cep-26401
- irdabisant
- irdabisant
- irdabisant
- irdabisant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01903824 | Phase 1 | Aug 1, 2013 | Teva |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Teva | For profit | 1 | 1 | 1 | 2013 |
1 organizations
Page 1 / 1